|
| PMBCL | cHL-NS | BCLu-DLBCL/cHL |
|
| Common features | | | |
| Age | Young patients | Young patients | Young patients |
| Gender | Female predominance | Female predominance | Male predominance |
| Localization | Mediastinal mass eventually supraclavicular lymph nodes | Mediastinal mass eventually supraclavicular lymph nodes | Mediastinal mass eventually supraclavicular lymph nodes or more rarely other lymph nodes |
| Morphology | Compartmentalizing fibrosis | Fibrosis in thick bands | Confluent, sheet like growth of pleomorphic tumor cells with diffuse fibrotic stroma Variability from area to area |
| Therapy response | Radiotherapy sensitive | Radiotherapy sensitive | |
| Immunophenotype | Lack of Ig-Expression
Lack of HLA I expression
Frequent CD30 expression
Expression of MAL and CD23 | Lack of Ig-expression
Lack of HLA I expression
CD30 expression | Transitional features between PMBCL and cHL
B-cell program often preserved |
| Genetic and molcular features | Expression of HLA-I
REL (2p15) and JAK2 gains (9p24)
CIITA breaks
Activation: NF-kappaB, JAK-STAT (incl. STAT6), and P13K/AKT pathway High expression of extracellular matrix elements, overexpression of TNF family members | Expression of HLA-I
REL (2p15) and JAK2 gains (9p24)
CIITA breaks
Activation: NF-kappaB, JAK-STAT (incl. STAT6), and P13K/AKT pathway
High expression of extracellular matrix elements, overexpression of TNF family members | REL (2p15) and JAK2 gains (9p24)
CIITA breaks |
|
| Distinguishing features | | | |
| Morphology | Clear cells often homogenous (but Reed Sternberg cells may occur)
Little or no inflammatory background | Hodgkin cells and Reed Sternberg cells
Typical inflammatory background | |
| Immunophenotype | B-cell markers preserved (CD20, CD79a, PAX5) B-cell transcription factors present (BOB.1 and OCT-2)
CD15 absent
Absence of EBV | B-cell markers lacking or only weakly or heterogeneously expressed (especially PAX5) B-cell transcription factors usually negative
CD15 may be present
EBV may be present | |
|
